Fate Therapeutics, Inc.
(NASDAQ : FATE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 20.57%329.630.0%$4354.99m
BNTXBioNTech SE 14.19%348.000.0%$1400.74m
NVAXNovavax, Inc. 8.95%217.9778.2%$1098.56m
AMGNAmgen, Inc. -1.41%201.091.4%$565.85m
LGVNLongeveron Inc. -27.49%30.670.0%$559.00m
REGNRegeneron Pharmaceuticals, Inc. -0.75%643.352.7%$495.48m
GILDGilead Sciences, Inc. 0.29%70.271.0%$491.04m
SNSSSunesis Pharmaceuticals, Inc. -8.16%4.840.7%$338.33m
VRTXVertex Pharmaceuticals, Inc. -1.42%183.591.9%$332.99m
OCGNOcugen, Inc. -9.16%6.450.0%$317.79m
ILMNIllumina, Inc. 1.16%369.793.3%$291.39m
BIIBBiogen, Inc. -2.89%242.901.8%$257.70m
BMRNBioMarin Pharmaceutical, Inc. -2.22%87.584.2%$157.02m
EXASEXACT Sciences Corp. -2.99%85.4618.0%$156.18m
INCYIncyte Corp. 2.46%68.382.4%$147.61m

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.